Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial - Quiz - MDSpire

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

  • By

  • Richard G. Langley

  • Lisa Arkin

  • Loretta Fiorillo

  • Lawrence F. Eichenfield

  • Mark Lebwohl

  • Bruce Strober

  • Michael Sticherling

  • Lisa Swanson

  • Georgios Kokolakis

  • Siddharth Chaudhari

  • Cynthia Deignan

  • Zuoshun Zhang

  • Amy S. Paller

  • May 14, 2026

  • 0 min

Share

Original Source(s)

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

  • by Richard G. Langley, Lisa Arkin, Loretta Fiorillo, Lawrence F. Eichenfield, Mark Lebwohl, Bruce Strober, Michael Sticherling, Lisa Swanson, Georgios Kokolakis, Siddharth Chaudhari, Cynthia Deignan, Zuoshun Zhang, Amy S. Paller

  • May 14, 2026

Related Content

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse